Tremor
TrialsCompanies

Not investment advice.

Tremor shows what changed in public records. It never tells anyone to buy or sell. Many trial edits are harmless paperwork. Data from ClinicalTrials.gov, the SEC, and the Federal Register.

PrivacyTerms

HCMHutchmedFinished

Tazemetostat for the Treatment of Relapsed/Refractory Follicular Lymphoma

Relapsed/Refractory Follicular Lymphoma With EZH2

10Calmworry score, out of 100

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

  • Main results were due Nov 2024, none posted yet

    Counts until it's fixed

    +10
Worry score10

Score over time

Stage
Phase 2
Patients
42 (final count)
Started
Jul 29, 2022
Main results expected
Nov 30, 2024
Fully finished
Nov 30, 2024
Results posted
not yet

What counts as success

The trial's main goal(s), called the “primary outcome.”

  • efficacy of Tazemetostat in EZH2 (MT) (Cohort 1)

    Measured over: 22 months

Changes Tremor has spotted

No changes since Tremor started watching this trial.
Show details (technical version)

Score inputs

  • results_overdue: base 10, now 10, since 2024-11-30, no fading

Raw record changes

  • none yet

Trial ID NCT05467943 · record last updated 2025-01-23 · checked 2026-11-09 15:47 UTC

See the official record on ClinicalTrials.gov (NCT05467943) ↗